Please wait a minute...
European Journal of Gynaecological Oncology  2020, Vol. 41 Issue (2): 163-166    DOI: 10.31083/j.ejgo.2020.02.4911
Systematic Review Previous articles | Next articles
Endometrial dedifferentiated carcinoma: a case report. Pathological review at a single institution and systematic review of published literature
T. Sakamoto1, M. Miyamoto1, *(), T. Kono2, H. Tsuada2, H. Matsuura1, T. Aoyama1, M. Takano3, K. Furuya1
1 Departments of Obstetrics and Gynecology, National Defense Medical College Hospital, Tokorozawa, Saitama, Japan
2 Basic Pathology, National Defense Medical College Hospital, Tokorozawa, Saitama, Japan
3 Clinical Oncology, National Defense Medical College Hospital, Tokorozawa, Saitama, Japan
Download:  PDF(1591KB)  ( 317 ) Full text   ( 10 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Background: Endometrial dedifferentiated carcinoma (DC) is a rare histological subtype with an unclear clinical outcome. Materiasl and Methods: The authors conducted a pathological review of patients with endometrial endometrioid carcinoma treated in this hospital between 1990 and 2013 according to 2014 World Health Organization criteria. They systematically reviewed PubMed literature and the present case concerning the clinical features of DC. Results: One (0.25%) of 375 DC patients was identified. A PubMed search detected 46 patients in 13 studies. Stage information was detailed in 45 patients, as follows: 9 (20%) Stage I, 5 (11%) Stage II, 10 (22%) Stage III, and 21 (47%) Stage IV. Surgical details were reported for 12 patients; 7 (58%) with complete resection, and 5 (42%) with incomplete resection. Early stage and complete resection improved overall survival (p < 0.01, p = 0.02, respectively). Conclusion: DC is a rare and aggressive histological subtype. Further research is needed to investigate new treatment strategies for DC.
Key words:  Endometrial carcinoma      Endometrioid carcinoma      Dedifferentiated carcinoma      Prognosis      Review     
Published:  15 April 2020     
*Corresponding Author(s):  M. MIYAMOTO     E-mail:  morikazu1118@hotmail.co.jp

Cite this article: 

T. Sakamoto, M. Miyamoto, T. Kono, H. Tsuada, H. Matsuura, T. Aoyama, M. Takano, K. Furuya. Endometrial dedifferentiated carcinoma: a case report. Pathological review at a single institution and systematic review of published literature. European Journal of Gynaecological Oncology, 2020, 41(2): 163-166.

URL: 

https://ejgo.imrpress.com/EN/10.31083/j.ejgo.2020.02.4911     OR     https://ejgo.imrpress.com/EN/Y2020/V41/I2/163

[1] Wook Youn Kim, Shin Hee Seo, Seung-Hyuk Shim, Jin Hee Park, Hyung Kyu Park, Kyeong A So, Tae Jin Kim, Sun Joo Lee. Correlation of immunohistochemistry and silver in situ hybridization for the assessment of c-MET in uterine cervical cancer patients treated with radical hysterectomy[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 745-752.
[2] Yi-fan Luo, Li-xiang Ren, Ming-yan Jiang, Yang Chu. A systematic review and meta-analysis on the effects of metformin on survival outcomes and risk in women with cervical cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 504-507.
[3] Chados Nikolaos, Gregoriou Odysseas, Salakos Nicolaos, Kondis Agatha, Deligeoroglou Efthymios. The prognostic significance and immuno-expression of survivin, mutant p53 and bcl-2 in 92 cases of epithelial ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 517-522.
[4] Sun Yi Choe, Jung-Woo Park. Prognostic significance of the number of metastatic lymph nodes in early cervical cancer: a retrospective study[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 536-540.
[5] J. An, G. Ruan, X.Y. Xie, Y.Q. Shi, X.D. Mao, B.H. Dong, P.M. Sun. Endometrial stromal nodule: report of 8 cases and literature review[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 332-338.
[6] B.-H. Zhang, L. Li, J. Ji, J. Guo, X.-L. Zhou, H. Xu, F. Cao, X.-H. Tong. Prognostic value of Foxp3+ regulatory T cells in endometrial cancer: a meta-analysis[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 339-342.
[7] Jingyuan Wang, Xiaoping Li, Danhua Shen, Xiao Wang, Zhiqi Wang, Jianliu Wang. Clear-cell carcinoma of the endometrium:type I or type II endometrial carcinoma?[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 449-454.
[8] M. Pakiž, A. Dovnik, B. Crnobrnja, P. Zola. Increased incidence of advanced stage endometrial cancer: a retrospective analysis of different clinical approaches and tumour biology[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 246-251.
[9] H. Wang, Y. Peng, Y. Liu, X. Li, A. Gu, H. He, M. Feng, D. Mao, L. Guo. Expression of HIWI in endometrial carcinoma tissues and its clinical significance[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 256-259.
[10] A. R. H. Ahmed, R. A. Bakheet, W. Abdelmohsen, M. Mohammed, M. A. Adly. Balance of glandular and stromal Bcl2/Bax expression in pre-neoplastic and neoplastic endometrial tissues[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 265-272.
[11] X.Q. Wang, S.Q. Ma, J.Y. Guo, F. Zhao, X.H. Liang. Characteristics and prognostic factors among premenopausal versus postmenopausal patients with advanced endometrial cancer: a SEER-based analysis[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 1-6.
[12] Y. Murata, Y. Miyahara, K. Suzuki, S. Wakahashi, T. Sudo, S. Nagao, S. Yamaguchi, Y. Ebina, H. Yamada. Leukocytosis and thrombocytosis as prognostic factors for women with uterine cervical cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 93-97.
[13] R. Pereira Souza, G. Pinheiro Soares, L. Valente Lage, G. Baiocchi, A.A.B.A. da Costa, M. del Pilar Eestevez Diz. Platinum rechallenge in second-line treatment for endometrial carcinoma[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 963-969.
[14] V. Loizzi, V. Del Vecchio, E. Pisani, G. Ranieri, L. Resta, E. Cicinelli, G. Cormio. Prognostic factors in endometrial cancer Stages III and IV: a single academic institution experience of 49 patients[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 1000-1005.
[15] A. Jaishuen, N. Boonkhum, J. Petsuksiri, N. Jareemit, P. Srichaikul, S. Therasakvichya. Outcomes of treatment for Stage III endometrial carcinoma patients[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 803-809.
No Suggested Reading articles found!